Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant human activated protein C (Xigris).

M Levi1, E De Jonge, T van der Poll

  • 1Department of Internal Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands.

International Journal of Clinical Practice
|September 26, 2002
PubMed
Summary

Severe sepsis treatment with recombinant activated protein C (Xigris) improves coagulation and reduces mortality. This therapy helps restore normal function and prevents harmful thrombin generation in sepsis patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From prediction to practice: early implementation of a machine learning-based hospitalization prediction tool in the emergency department.

International journal of medical informatics·2026
Same author

Atypical Resting-State EEG Graph Metrics of Network Efficiency Across Development in Autism and Their Association with Social Cognition: Results from the LEAP Study.

Journal of autism and developmental disorders·2025
Same author

Oxygen consumption, effort, and weaning in the mechanically ventilated patient in the intensive care unit: The extubate study: A protocol for an observational study.

Respiratory medicine·2025
Same author

Transvaginal uterine niche repair: surgical technique and outcome.

Facts, views & vision in ObGyn·2024
Same author

Volume of oxygen administered during mechanical ventilation predicts mortality in ICU patients.

Critical care (London, England)·2023
Same author

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.

Breast cancer research and treatment·2023

Area of Science:

  • Biochemistry
  • Pathophysiology
  • Pharmacology

Background:

  • Sepsis involves impaired protein C pathway function, leading to coagulation disorders and microvascular thrombosis.
  • Activated protein C (APC) plays a crucial role in regulating coagulation and inflammation.

Purpose of the Study:

  • To evaluate the efficacy of human recombinant activated protein C (Xigris) in treating severe sepsis.
  • To assess APC's ability to restore anticoagulant mechanisms and modulate inflammatory responses.

Main Methods:

  • Review of experimental studies on APC in sepsis models.
  • Analysis of randomized controlled clinical trials involving severe sepsis patients treated with Xigris.

Main Results:

  • Experimental data showed APC administration inhibited coagulation derangement, reduced inflammation, and preserved organ function.

Related Experiment Videos

  • Clinical trials confirmed that Xigris administration reduced mortality in severe sepsis patients.

    • Conclusions:

    • Recombinant activated protein C (Xigris) demonstrates significant therapeutic benefits in severe sepsis.
    • APC therapy effectively addresses both the pro-coagulant and pro-inflammatory aspects of sepsis pathogenesis.